tiprankstipranks
Dexcom (DXCM)
NASDAQ:DXCM
US Market
DXCM
Dexcom
RESEARCH TOOLSreports

Dexcom (DXCM) Stock Forecast & Price Target

4,396 Followers
See the Price Targets and Ratings of:

DXCM Analyst Ratings

Strong Buy
20Ratings
Strong Buy
17 Buy
2 Hold
1 Sell
Based on 20 analysts giving stock ratings to
Dexcom
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DXCM Stock 12 Month Forecast

Average Price Target

$86.76
▲(39.44% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $86.76 with a high forecast of $112.00 and a low forecast of $72.00. The average price target represents a 39.44% change from the last price of $62.22.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"$57","71":"$71","85":"$85","99":"$99","113":"$113"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$86.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$72.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,71,85,99,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.37,66.1876923076923,70.00538461538461,73.82307692307693,77.64076923076922,81.45846153846153,85.27615384615385,89.09384615384616,92.91153846153846,96.72923076923077,100.54692307692306,104.36461538461538,108.18230769230769,{"y":112,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.37,64.24615384615385,66.12230769230769,67.99846153846154,69.87461538461538,71.75076923076924,73.62692307692308,75.50307692307692,77.37923076923077,79.25538461538461,81.13153846153847,83.00769230769231,84.88384615384615,{"y":86.76,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.37,63.11076923076923,63.85153846153846,64.59230769230768,65.33307692307692,66.07384615384615,66.81461538461538,67.55538461538461,68.29615384615384,69.03692307692307,69.7776923076923,70.51846153846154,71.25923076923077,{"y":72,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":67.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.37,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.37,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$112.00Average Price Target$86.76Lowest Price Target$72.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on DXCM
Josh Jennings
TD Cowen
TD Cowen
$84
Buy
35.00%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and Dexcom (NASDAQ: DXCM)
Citi Analyst forecast on DXCM
Joanne Wuensch
Citi
Citi
$77→$84
Buy
35.00%
Upside
Assigned
03/12/26
DexCom price target raised to $84 from $77 at CitiDexCom price target raised to $84 from $77 at Citi
BTIG Analyst forecast on DXCM
Marie Thibault
BTIG
BTIG
$85
Buy
36.61%
Upside
Reiterated
03/09/26
Analysts Are Bullish on These Healthcare Stocks: Dexcom (DXCM), Medline (MDLN)
Jefferies Analyst forecast on DXCM
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$112
Buy
80.01%
Upside
Reiterated
03/02/26
Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)
Truist Financial Analyst forecast on DXCM
Richard Newitter
Truist Financial
Truist Financial
$82→$80
Buy
28.58%
Upside
Reiterated
02/17/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)
Robert W. Baird Analyst forecast on DXCM
Jeff Johnson
Robert W. Baird
Robert W. Baird
$82→$87
Buy
39.83%
Upside
Reiterated
02/13/26
DexCom price target raised to $87 from $82 at BairdDexCom price target raised to $87 from $82 at Baird
Oppenheimer Analyst forecast on DXCM
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
02/13/26
Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), American Well (NYSE: AMWL) and Avita Medical (NASDAQ: RCEL)
Mizuho Securities Analyst forecast on DXCM
Anthony Petrone
Mizuho Securities
Mizuho Securities
$78→$90
Buy
44.65%
Upside
Reiterated
02/13/26
DexCom price target raised to $90 from $78 at MizuhoDexCom price target raised to $90 from $78 at Mizuho
Stifel Nicolaus Analyst forecast on DXCM
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$85
Buy
36.61%
Upside
Reiterated
02/13/26
Stifel Nicolaus Keeps Their Buy Rating on Dexcom (DXCM)
Barclays Analyst forecast on DXCM
Matt Miksic
Barclays
Barclays
$71→$72
Sell
15.72%
Upside
Reiterated
02/13/26
UBS Analyst forecast on DXCM
Danielle Antalffy
UBS
UBS
$95
Buy
52.68%
Upside
Reiterated
02/13/26
Analysts Conflicted on These Healthcare Names: Rezolute (NASDAQ: RZLT), Dexcom (NASDAQ: DXCM) and Bruker (NASDAQ: BRKR)
Bank of America Securities Analyst forecast on DXCM
Travis Steed
Bank of America Securities
Bank of America Securities
$100
Buy
60.72%
Upside
Reiterated
02/13/26
Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)
Canaccord Genuity Analyst forecast on DXCM
William Plovanic
Canaccord Genuity
Canaccord Genuity
$99→$95
Buy
52.68%
Upside
Reiterated
02/13/26
DexCom price target lowered to $95 from $99 at CanaccordDexCom price target lowered to $95 from $99 at Canaccord
Wells Fargo Analyst forecast on DXCM
Larry Biegelsen
Wells Fargo
Wells Fargo
$93→$85
Buy
36.61%
Upside
Reiterated
02/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NASDAQ: NBIX), Dexcom (NASDAQ: DXCM) and Icon (NASDAQ: ICLR)
Morgan Stanley Analyst forecast on DXCM
Patrick Wood
Morgan Stanley
Morgan Stanley
$75
Buy
20.54%
Upside
Reiterated
02/13/26
Morgan Stanley Sticks to Its Buy Rating for Dexcom (DXCM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on DXCM
Josh Jennings
TD Cowen
TD Cowen
$84
Buy
35.00%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX) and Dexcom (NASDAQ: DXCM)
Citi Analyst forecast on DXCM
Joanne Wuensch
Citi
Citi
$77→$84
Buy
35.00%
Upside
Assigned
03/12/26
DexCom price target raised to $84 from $77 at CitiDexCom price target raised to $84 from $77 at Citi
BTIG Analyst forecast on DXCM
Marie Thibault
BTIG
BTIG
$85
Buy
36.61%
Upside
Reiterated
03/09/26
Analysts Are Bullish on These Healthcare Stocks: Dexcom (DXCM), Medline (MDLN)
Jefferies Analyst forecast on DXCM
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$112
Buy
80.01%
Upside
Reiterated
03/02/26
Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)
Truist Financial Analyst forecast on DXCM
Richard Newitter
Truist Financial
Truist Financial
$82→$80
Buy
28.58%
Upside
Reiterated
02/17/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)
Robert W. Baird Analyst forecast on DXCM
Jeff Johnson
Robert W. Baird
Robert W. Baird
$82→$87
Buy
39.83%
Upside
Reiterated
02/13/26
DexCom price target raised to $87 from $82 at BairdDexCom price target raised to $87 from $82 at Baird
Oppenheimer Analyst forecast on DXCM
Suraj Kalia
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
02/13/26
Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), American Well (NYSE: AMWL) and Avita Medical (NASDAQ: RCEL)
Mizuho Securities Analyst forecast on DXCM
Anthony Petrone
Mizuho Securities
Mizuho Securities
$78→$90
Buy
44.65%
Upside
Reiterated
02/13/26
DexCom price target raised to $90 from $78 at MizuhoDexCom price target raised to $90 from $78 at Mizuho
Stifel Nicolaus Analyst forecast on DXCM
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$85
Buy
36.61%
Upside
Reiterated
02/13/26
Stifel Nicolaus Keeps Their Buy Rating on Dexcom (DXCM)
Barclays Analyst forecast on DXCM
Matt Miksic
Barclays
Barclays
$71→$72
Sell
15.72%
Upside
Reiterated
02/13/26
UBS Analyst forecast on DXCM
Danielle Antalffy
UBS
UBS
$95
Buy
52.68%
Upside
Reiterated
02/13/26
Analysts Conflicted on These Healthcare Names: Rezolute (NASDAQ: RZLT), Dexcom (NASDAQ: DXCM) and Bruker (NASDAQ: BRKR)
Bank of America Securities Analyst forecast on DXCM
Travis Steed
Bank of America Securities
Bank of America Securities
$100
Buy
60.72%
Upside
Reiterated
02/13/26
Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)
Canaccord Genuity Analyst forecast on DXCM
William Plovanic
Canaccord Genuity
Canaccord Genuity
$99→$95
Buy
52.68%
Upside
Reiterated
02/13/26
DexCom price target lowered to $95 from $99 at CanaccordDexCom price target lowered to $95 from $99 at Canaccord
Wells Fargo Analyst forecast on DXCM
Larry Biegelsen
Wells Fargo
Wells Fargo
$93→$85
Buy
36.61%
Upside
Reiterated
02/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NASDAQ: NBIX), Dexcom (NASDAQ: DXCM) and Icon (NASDAQ: ICLR)
Morgan Stanley Analyst forecast on DXCM
Patrick Wood
Morgan Stanley
Morgan Stanley
$75
Buy
20.54%
Upside
Reiterated
02/13/26
Morgan Stanley Sticks to Its Buy Rating for Dexcom (DXCM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

3 Months
xxx
Success Rate
12/18 ratings generated profit
67%
Average Return
+3.93%
reiterated a xxx
 rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.93% per trade.
1 Year
Jeff JohnsonRobert W. Baird
Success Rate
21/41 ratings generated profit
51%
Average Return
+9.25%
reiterated a buy rating 2 months ago
Copying Jeff Johnson's trades and holding each position for 1 Year would result in 51.22% of your transactions generating a profit, with an average return of +9.25% per trade.
2 Years
xxx
Success Rate
19/34 ratings generated profit
56%
Average Return
+24.99%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 55.88% of your transactions generating a profit, with an average return of +24.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DXCM Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
9
4
1
2
2
Buy
39
41
62
63
48
Hold
14
11
12
12
8
Sell
0
1
2
2
1
Strong Sell
0
0
0
0
0
total
62
57
77
79
59
In the current month, DXCM has received 50 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. DXCM average Analyst price target in the past 3 months is 86.76.
Each month's total comprises the sum of three months' worth of ratings.

DXCM Financial Forecast

DXCM Earnings Forecast

Next quarter’s earnings estimate for DXCM is $0.47 with a range of $0.39 to $0.53. The previous quarter’s EPS was $0.68. DXCM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.
Next quarter’s earnings estimate for DXCM is $0.47 with a range of $0.39 to $0.53. The previous quarter’s EPS was $0.68. DXCM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Sales Forecast

Next quarter’s sales forecast for DXCM is $1.17B with a range of $1.16B to $1.18B. The previous quarter’s sales results were $1.26B. DXCM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.
Next quarter’s sales forecast for DXCM is $1.17B with a range of $1.16B to $1.18B. The previous quarter’s sales results were $1.26B. DXCM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Stock Forecast FAQ

What is DXCM’s average 12-month price target, according to analysts?
Based on analyst ratings, Dexcom’s 12-month average price target is 86.76.
    What is DXCM’s upside potential, based on the analysts’ average price target?
    Dexcom has 39.44% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DXCM a Buy, Sell or Hold?
          Dexcom has a consensus rating of Strong Buy which is based on 17 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Dexcom’s price target?
            The average price target for Dexcom is 86.76. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $112.00 ,the lowest forecast is $72.00. The average price target represents 39.44% Increase from the current price of $62.22.
              What do analysts say about Dexcom?
              Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of DXCM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.